Try Alerts Free   |   Login
Health Care › Biological Products (No Diagnostic Substances)

Titan Pharmaceuticals (TTNP) Financials and Smart Investor 13F Alerts

See how revenue, income, cash flow, and balance sheet financials have changed over 36 quarters since 2012. Compare with TTNP stock chart to see long term trends.

TTNP stock compared to

TTNP Income Statement

Revenue, Net:1057000
Revenue Per Share:0.28
Cost of Goods & Services Sold:-610000
Selling, General & Admin Expense:null
Research & Development Expense:70000
Total Operating Expenses:-4876000
Operating Income:5933000
Net Income:-3085000
Earnings Per Share, Basic:3.14
Shares Outstanding, Basic Avg:3773000

TTNP Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:65000
Change in Accounts Receiveable:384000
Net Cash from Operations:-4561000
Net Cash from Financing Activities:5910000
Property, Plant & Equipment Purchases:9000
Net Cash from Investing Activities:-9000
Net Change in Cash & Equivalents:1340000

TTNP Balance Sheet

Cash and Cash Equivalents:5413000
Accounts Receivable, Net:884000
Total Current Assets:7328000
Property, Plant & Equipment, Net:618000
Total Assets:8087000
Accounts Payable:1253000
Current Portion of Long-Term Debt:327000
Total Short-Term Liabilities:4223000
Long Term Debt, Non-Current Portion:332000
Total Liabilities:4555000

Major Holders (from 13F filings)

Investment Type
Value (x$1000)
increase or decrease
Sabby Management, LLC
4,856,723 sh
4,856,723 sh
Vanguard Group Inc
1,150,903 sh
Northern Trust Corp
192,724 sh
Bank Of America Corp /De/
6,125 sh
Blackrock Inc.
1,839 sh
Morgan Stanley
419 sh
Royal Bank Of Canada
5 sh
Virtu Financial LLC
0 sh
-142,611 sh
Tru Independence LLC
0 sh
-15,625 sh
Proequities, Inc.
0 sh

Data imported from Titan Pharmaceuticals Inc SEC filings. Check original filings before making any investment decision.